Thalidomide Embryopathy Surveillance in Brazil
Author Information
Author(s): Vianna Fernanda Sales Luiz, Lopez-Camelo Jorge S., Leite Júlio César Louguercio, Sanseverino Maria Teresa Vieira, Dutra Maria da Graça, Castilla Eduardo E., Schüler-Faccini Lavínia
Primary Institution: INAGEMP (Instituto Nacional de Genética Médica Populacional)
Hypothesis
The study aimed to implement a proactive surveillance system to identify birth defects compatible with thalidomide embryopathy (TE).
Conclusion
The proactive surveillance identified an increased frequency of thalidomide embryopathy phenotype (TEP) in Brazil, suggesting a need for continuous monitoring.
Supporting Evidence
- The frequency of TEP during the surveillance period was significantly higher than in the baseline period.
- Two cases of suspected thalidomide embryopathy were identified during the proactive surveillance.
- The study covered 1,145,214 births across 56 Brazilian hospitals.
- Thalidomide was linked to severe limb reduction defects in children born in Brazil.
- Monitoring systems are crucial for detecting increases in birth defects related to thalidomide.
Takeaway
The study looked at babies born with limb defects in Brazil to see if thalidomide, a harmful drug, was causing more problems. They found that more babies had issues than before.
Methodology
The study used a proactive surveillance system to monitor newborns with limb reduction defects across Brazilian hospitals over a one-year period.
Potential Biases
The study may be biased due to improved prenatal diagnosis leading to higher reported rates of limb reduction defects.
Limitations
The main endemic areas of leprosy are in rural regions where monitoring is less effective, and the study may not capture all cases of thalidomide embryopathy.
Participant Demographics
The study included newborns from various regions in Brazil, particularly focusing on areas with high leprosy prevalence.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI: 2.50–3.70
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website